Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’
Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu). Medscape Medical News …read more